Paul Mampilly is an investment advisor and stock market analyst. Born in India, Paul moved to United Stated his career in the financial sector as a young man. In the over 25 years he has been in the business, he has proved to be a resourceful investment analyst and even held high ranking positions at some of the best firms like Deutsche Bank.
Wall Street work was not enough for him; Paul Mampilly eventually left the hedge funds to venture into private business. Nevertheless, that was not after making the companies there a lot of money. According to Kinetics Asset Management, during Paul’s tenure there as a hedge fund manager, the company saw an average 26% annual return raising the firm’s portfolio from $6 billion to $25 billion.
Investing in stocks can be challenging and extremely risky for the average untrained individual. This fact was a great motivator for Paul’s decision to start an investment newsletter ‘Profits Unlimited’ that gives valuable guidance to its over 90,000 subscribers. He continues to advise people on the volatile and risky stock market industry helping them make good returns on their investment.
Follow Paul Mampilly on LinkedIn
Companies manufacturing Electric cars is one of the key investment options that Paul Mampilly advises new investors. He believes that with the rapid change in technology and the efficiency that electric vehicles offer customers, they are the stocks to watch. The cars are easy to maintain as only three of their parts need maintenance.
The food industry is another lucrative venture according to Paul Mampily on talkmarkets.com. More people are seeking fast and healthy food delivered to their doorsteps. This trend has resulted in various businesses venturing into food delivery services. Paul advises investors to put their money into such enterprises since, in the near future, their stock value will be very lucrative.
With the advancement in health science technology, Paul sees promising growth in the medical industry. The latest progress in precision medicine where doctors can now treat individuals based on their genetic composition. A patient’s genetic information is used to determine the best medication and even predict what types of illnesses are likely to infect the individual. Paul’s advice is for investors to look out for companies that have embraced this technology and invest in them.
Find more about Paul Mampilly: https://technewsspy.com/2017/08/23/paul-mampilly-investment-advice-electric-vehicles-food-delivery-precision-medicine/